Drugs / [18F]CTT1057
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04838626 | Sep 2021 → Nov 2023 | prostate cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04838613 | Sep 2021 → Nov 2023 | prostate cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]CTT1057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04838626 ↗ |
| Modality | Diagnostic / imaging agent | “PSMA-targeted PET radiotracer [18F]CTT1057” PMID 40473464 ↗ Aug 2025 |
| Route | Intravenous | “Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan” NCT04838613 ↗ |